Assessment of potential thrombogenicity of coagulation factor IX concentrates in an in vitro model of human thrombogenesis

Thrombosis Research

Volumn 96, Issue 5, 1999, Pages 383-389

  Galan, Ana M ^a   Reverter, Juan Carlos ^a   Bozzo, Jordi ^a   Hernandez, M Rosa ^a   Escolar, Gines ^a   Aznar Salatti, Jose ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Centeon SA   (Spain)

Author keywords

Factor IX concentrates; In vitro assessment; Thrombogenicity

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 COMPLEX; PROTHROMBIN COMPLEX;

ANIMAL TISSUE; AORTA; ARTICLE; BLOOD CLOTTING; FIBRIN DEPOSITION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MORPHOMETRICS; NONHUMAN; NORMAL HUMAN; PERFUSION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOGENICITY;

ANIMALS; BLOOD COAGULATION FACTORS; DISEASE MODELS, ANIMAL; FIBRIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PEPTIDE FRAGMENTS; PERFUSION; PROTHROMBIN; RABBITS; THROMBOSIS;

EID: 0032801401     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00134-6     Document Type: Article

References (30)

1. Kasper C.K. Clinical use of prothrombin complex concentrates. Report on thromboembolic complications. Thromb Diath Haemorrh. 33:1975;640-644.
2. Lusher J.M. Thrombogenicity associated with factor IX complex concentrates. Sem Hematol. 28(Suppl 6):1991;3-5.
3. Hultin M.B. Activated clotting factors in factor IX concentrates. Blood. 54:1979;1028-1038.
4. Hellstern P., Beeck H., Fellhauer A., Fischer A., Faller-Stöckl B. Factor VII and activated factor VII content of prothrombin complex concentrates. Vox Sang. 73:1997;155-161.
5. Kim H.C., McMillan C.V., White G.C., Bergman G.E., Horton M.W., Saidi P. Purified factor IX using monoclonal immunoaffinity technique. Clinical trials in hemophilia B and comparison with prothrombin complex concentrates Blood. 79:1992;568-575.
6. Menache D., Behre H.E., Orthner C.L., Nunez H., Anderson H.D., Triantaphyllopoulos D.C., Kosow D.P. Coagulation factor IX concentrate. Method of preparation and assessment of potential in vivo thrombogenicity in animal models Blood. 64:1984;1220-1227.
7. Herring S.W., Albildgaard C., Shitanishi K.T., Harrison J., Gendler S., Heldebrandt C.M. Human coagulation factor IX. Assessment of thrombogenicity in animal models and viral safety J Lab Clin Med. 121:1993;294-405.
8. Hampton K.K., Preston F.E., Lowe G.D.O., Walker I.D., Sampson B. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haem. 84:1993;279-284.
9. Ohga S., Saito M., Matsukazi A., Kai T., Ueda K. Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy. Br J Haem. 84:1993;343-345.
10. Limentani S.A., Gowell K.P., Deitcher S.R. In vitro characterization of high purity factor IX concentrates for the treatment of hemophilia B. Thromb Haemost. 73:1995;584-591.
11. Kasper C.K. Postoperative thrombosis in hemophilia B. N Engl J Med. 289:1973;160.
12. Gray E., Tubbs J., Thomas S., Oates A., Boisclair M., Kemball-Cook G., Barrowcliffe T.W. Measurement of activated factor IX in factor IX concentrates. Correlation with thrombogenicity Thromb Haemost. 73:1995;675-679.
13. Bauer K.A., Rosenberg R.D. The pathophysiology of the prothrombotic state in humans. Insights gained from studies using markers of hemostatic system activation Blood. 70:1987;343-350.
14. Baumgartner H.R. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res. 5:1973;167-179.
15. Zwaginga J.J., Sixma J.J., de Groot P.G. Activation of endothelial cells induces platelet thrombus formation on their matrix. Studies of new in vitro thrombosis model with low molecular weight heparin as anticoagulant. Arteriosclerosis. 10:1990;49-61.
16. Escolar G., Bastida E., Ordinas A., Castillo R. Development of a computer program to analyze the parameters of platelet-vessel wall interaction. Hemostasis. 16:1986;8-14.
17. Cofrancesco E., Cortellaro M., Corradi A., Ravasi F., Bertocchi F. Coagulation activation markers in the prediction of venous thrombosis after elective hip surgery. Thromb Haemost. 77:1997;267-269.
18. Pelzer H., Schwartz A., Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost. 65:1991;153-159.
19. Wessler S., Reimer S.M., Sheps M.C. Biologic assay of thrombosis inducing activity in human serum. J Appl Physiol. 14:1959;943-946.
20. Committee for Proprietary Medicinal Products. Replacement of animal studies by in vitro models. EEC, February, 1997.
21. MacGregor I., McLaughlin L., Drummond O., Prowse C., Ferguson J. In vivo models of thrombogenic potential. Usefulness and limitations Acta Haematol. 94(Suppl 1):1995;18-23.
22. Weiss H.J. Flow-related platelet deposition on subendothelium. Thromb Haemost. 74:1995;117-122.
23. Lozano M., Bos A., de Groot P.G., VanWilligen G., Meuleman D.G., Ordinas A., Sixma J.J. Suitability of low-molecular-weight hepari(oid)s and a pentasaccharide for an in vitro human thrombosis model. Arteriosclerosis and Thrombosis. 14:1994;1215-1222.
24. De Groot P.G., Reinders J.H., Sixma J.J. Perturbation of human endothelial cells by thrombin or PMA changes the reactivity of their extracellular matrix towards platelets. J Cell Biol. 104:1987;697-704.
25. Hernández M.R., Bozzo J., Mazzara R., Ordinas A., Escolar G. Platelet concentrates promote procoagulant activity. Evidence from experimental studies using a perfusion technique Transfusion. 35:1995;660-665.
26. Mannucci P.M., Bauer K.A., Gringeri A., Barzegar S., Santagostino E., Tradati F.C., Rosenberg R.D. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol. 79:1991;606-611.
27. Zwaginga J.J., de Boer H.C., Ijsseldijk M.J.W., Kerkhof A., Muller-Berghaus G., Gruhlich J., Sixma J.J., de Groot P.G. Thrombogenicity of vascular cells. Comparison between. Arteriosclerosis. 10:1990;437-448.
28. Lundbland R.L., Bergstrom J., De Vreker R., Bray G., Gomperts E., Baker D., Kingdom H.S., Mann K.G., Hartshorn J., Jenny R.J. Measurement of active coagulation factors in Autoplex (R)-T with colorimetric active site-specific assay technology. Thromb Haemost. 80:1998;811-815.
29. Mannucci P.M., Bauer K.A., Gringeri A., Barzegar S., Bottasso B., Simoni L., Rosenberg R.D. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood. 76:1990;2540-2545.
30. Guidelines on oral anticoagulation, 2d edition. J Clin Pathol. 43:1990;177-183.